^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + pertuzumab zuvotolimod (SBT6050) (HER2-targeted antibody-drug conjugate, TLR8 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
209P - Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors
Published date:
09/13/2021
Excerpt:
Patients have HER2-expressing or -amplified solid tumors...In response-evaluable patients (N=14), best overall response was PR (n=1), SD (n=3), and PD (n=10)….Based on preliminary safety data, SBT6050 given alone or in combination with pembrolizumab has a manageable safety profile.
Trial ID:
